Divalproex Sodium Tablet, Delayed Release
Product Images NDC 50090-4861

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 50090-4861). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 01

Chemical structure diagram of Divalproex Sodium, showing the molecular formula arrangement with sodium ions and organic groups indicated.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 02

A bar chart comparing percentages for Divalproex Sodium (DVPX) and placebo (PBO) across two studies measured in years. The chart shows higher percentages for DVPX groups in both Study 1 (YMRs) and Study 2 (MRS), with values of 60% and 58% respectively, versus placebo groups at 26% and 29%.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 03

A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium and placebo across the percentage of patients. The vertical axis represents the change in CPS rate from worsening to improvement, while the horizontal axis shows the percentage of patients, with Divalproex Sodium represented by a solid line and placebo by a dotted line.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 04

A line chart depicting the percentage reduction in CPS rate versus the percentage of patients. It compares outcomes for high dose (solid line) and low dose (dashed line) treatment groups, showing improvement and worsening along the vertical axis.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 05

This image shows a bar graph comparing two studies. Each study compares Placebo to Divalproex Sodium, with vertical bars representing relative values. The graph visually contrasts the effects or measurements for Placebo and Divalproex Sodium groups across two separate studies.*

FDA Label Image

39cef9df 868d 4963 B0a7 7f146275442f 06

FDA Label Image

Label Image (Lbl500904861)

Divalproex Sodium 125 mg delayed-release tablets packaging label from A-S Medication Solutions. The label includes product NDC 50090-4861, specifies the oral route, storage instructions at 68 to 77 degrees F, and indicates a count of 30 tablets per package. The label also provides drug equivalency information and a QR code for dosage package insert details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.